Apellis Pharmaceuticals (APLS) Research & Development: 2020-2025
Historic Research & Development for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $68.2 million.
- Apellis Pharmaceuticals' Research & Development fell 23.01% to $68.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $298.0 million, marking a year-over-year decrease of 7.03%. This contributed to the annual value of $327.6 million for FY2024, which is 7.57% down from last year.
- Latest data reveals that Apellis Pharmaceuticals reported Research & Development of $68.2 million as of Q3 2025, which was up 1.75% from $67.0 million recorded in Q2 2025.
- Apellis Pharmaceuticals' Research & Development's 5-year high stood at $110.0 million during Q1 2023, with a 5-year trough of $67.0 million in Q2 2025.
- In the last 3 years, Apellis Pharmaceuticals' Research & Development had a median value of $79.4 million in 2023 and averaged $82.1 million.
- Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 55.32% in 2021, then slumped by 30.32% in 2023.
- Apellis Pharmaceuticals' Research & Development (Quarterly) stood at $78.2 million in 2021, then climbed by 27.17% to $99.4 million in 2022, then tumbled by 30.32% to $69.3 million in 2023, then climbed by 10.21% to $76.4 million in 2024, then decreased by 23.01% to $68.2 million in 2025.
- Its Research & Development was $68.2 million in Q3 2025, compared to $67.0 million in Q2 2025 and $86.4 million in Q1 2025.